– USA, CA – Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes and A Proliferation Inducing Ligand pathways, today announced the appointment of Frank Karbe to its Board of Directors and Audit Committee. Mr. Karbe, who currently serves as the chief financial officer of Myovant Sciences, Inc., brings more than 20 years of life sciences industry experience to Aduro.
“We are pleased to welcome Frank to our Board as we continue advancing our STING and APRIL programs through development,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Frank’s track record of leadership in financial strategy, operations and corporate development will be a valuable addition to Aduro.”
“This is an exciting time for Aduro, as its first-in-class STING agonist and anti-APRIL antibody have the potential to impact the treatment of multiple oncologic, autoimmune and inflammatory indications,” added Mr. Karbe. “I look forward to collaborating with Aduro’s Board and executive leadership team on the company’s next phase of growth and development.”
Prior to joining Myovant Sciences, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, Mr. Karbe served as executive vice president and chief financial officer for Exelixis from 2004 – 2014. Earlier in his career, he worked as an investment banker for Goldman Sachs & Co., most recently as vice president in the healthcare group focusing on corporate finance and mergers and acquisitions in the biotechnology industry. He also served on the Board of Directors of Arbutus Biopharma Corporation and Kolltan Pharmaceuticals, Inc. Mr. Karbe received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.
Aduro Biotech, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies that are designed to harness the body’s natural immune system for the treatment of patients with challenging diseases. Aduro’s product candidates in the Stimulator of Interferon Genes and A Proliferation Inducing Ligand pathways are being investigated in cancer, autoimmune and inflammatory diseases. ADU-S100 (MIW815), which potentially activates the intracellular STING receptor for a potent tumor-specific immune response, is being evaluated in patients with cutaneously accessible metastatic solid tumors or lymphomas. BION-1301, a fully blocking monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, is being evaluated in multiple myeloma and as a potential treatment for IgA nephropathy. Aduro is collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline.
For more information : https://www.aduro.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.